{"title": "Madrigal's NASH prospect clears first phase 3 test, raising hopes it can magic up positive pivotal efficacy data", "author": "Nick Paul Taylor", "url": "https://www.fiercebiotech.com/biotech/madrigal-s-nash-prospect-clears-first-phase-3-test-raising-hopes-it-can-magic-up-positive", "hostname": "fiercebiotech.com", "description": "Madrigal Pharmaceuticals has passed the first of two phase 3 | Madrigal Pharmaceuticals has passed the first of two phase 3 nonalcoholic steatohepatitis (NASH) trials. With the study finding the ex-Roche drug reduces liver fat, Madrigal is heading to a more comprehensive efficacy readout with increased confidence in its chances of bucking the industry's NASH losing streak.", "sitename": "FierceBiotech", "date": "2022-01-31", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}